Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.
Saved in:
| Title: | Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study. |
|---|---|
| Authors: | Greil R; IIIrd Medical Department Paracelsus Medical University, Salzburg Cancer Research Institute-CCCIT, Cancer Cluster Salzburg, Salzburg, Austria. r.greil@salk.at., Tedeschi A; Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy., Moreno C; Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain., Anz B; Department of Medical Oncology, Tennessee Oncology, Chattanooga, TN, USA., Larratt L; Department of Clinical Hematology, University of Alberta Hospital, Edmonton, Alberta, Canada., Simkovic M; Department of Internal Medicine - Hematology, University Hospital and Medical School Hradec Králové, Hradec Králové, Czech Republic., Gill D; Department of Clinical Hematology, Princess Alexandra Hospital, Brisbane, Queensland, Australia., Gribben JG; Centre for Haemato-Oncology, Queen Mary University of London, Barts Cancer Institute, London, UK., Flinn IW; Center for Blood Cancers, Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA., Wang Z; Translational Medicine, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA., Cheung LWK; Translational Medicine, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA., Nguyen AN; Translational Medicine, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA., Zhou C; Biostatistics, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA., Styles L; Clinical Science, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA., Demirkan F; Department of Hematology, Dokuz Eylül University, Izmir, Turkey. |
| Source: | Annals of hematology [Ann Hematol] 2021 Jul; Vol. 100 (7), pp. 1733-1742. Date of Electronic Publication: 2021 May 20. |
| Publication Type: | Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-0584 |
|---|---|
| DOI: | 10.1007/s00277-021-04536-6 |
